EU signs deal with GSK for supply of potential COVID drug

[ASFN Admin]

The European Union has signed a contract with GlaxoSmithKline for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab against COVID-19, it said on Wednesday. The drug, which is developed together with U.S. firm Vir Biotechnology, can be used for the treatment of high-risk coronavirus patients with mild symptoms who do not require supplemental oxygen, according to the Commission. The deal is a boost to GSK work on potential treatments for COVID-19 after the company played a limited role in the development of vaccines.

Continue reading...